Patients with canceled breast biopsies due to nonvisualization require follow-up MRI

A study recently published in Academic Radiology has found that follow-up imaging after a canceled MRI-guided breast biopsy due to nonvisualization may accurately indicate completely resolved breast lesions. But because some lesions do persist after the initial biopsy, researchers recommend six-month follow-up MRI exams for patients.

“Because of the possibility that a malignancy may have been missed at the time of cancellation, a short-term interval follow-up examination remains a prudent course of action,” wrote lead author Samantha Heller, MD, PhD, a radiologist at the Laura Perlmutter Center for Biomedical Imaging at the New York University School of Medicine, and colleagues. “In addition, lesions that have completely resolved or are smaller on follow-up MRI imaging (at least six months post MRI-biopsy cancellation) do not need further follow-up.” 

According to study methods, Heller and colleagues studied the medical records of 54 biopsies from 2007 to 2014 canceled due to nonvisualization. More than 74 percent of patients had lesions completely resolved by the time of their follow up imaging exam, but the remaining 26 percent had lesions that persisted after follow-up MRI. Half of those patients then underwent a biopsy, according to study methods.  

"One case yielded ductal carcinoma in situ with microinvasion at the six-month follow-up," Heller et al. noted. "No patient demographics or lesion features were associated with lesion resolution or lesion biopsy." 

Overall, despite study findings regarding the great amount of breast lesion resolve, researchers recommended that patients do undergo follow-up examinations to prevent any missed malignancies.

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.